Angeion's defibrillator lead to undergo US trials:
This article was originally published in Clinica
Angeion plans to begin a US multicentre clinical trial of its new AngeFix 4090 lead system for defibrillators. The lead helps pace, sense and defibrillate the heart using a helix-shaped active fixation tip which can be "screwed" into the heart tissue and which also reduces the risk of the lead becoming dislodged. The Minneapolis, Minnesota-based company recently CE-marked the device which will be marketed in Europe by ELA Medical, a subsidiary of French company Synthelabo.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.